SAN

75.15

+1.06%↑

ARGX

685.6

+1.51%↑

SHL.DE

33.97

+0.95%↑

FRE

39.65

+1.33%↑

PHIA

22.5

+1.03%↑

SAN

75.15

+1.06%↑

ARGX

685.6

+1.51%↑

SHL.DE

33.97

+0.95%↑

FRE

39.65

+1.33%↑

PHIA

22.5

+1.03%↑

SAN

75.15

+1.06%↑

ARGX

685.6

+1.51%↑

SHL.DE

33.97

+0.95%↑

FRE

39.65

+1.33%↑

PHIA

22.5

+1.03%↑

SAN

75.15

+1.06%↑

ARGX

685.6

+1.51%↑

SHL.DE

33.97

+0.95%↑

FRE

39.65

+1.33%↑

PHIA

22.5

+1.03%↑

SAN

75.15

+1.06%↑

ARGX

685.6

+1.51%↑

SHL.DE

33.97

+0.95%↑

FRE

39.65

+1.33%↑

PHIA

22.5

+1.03%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

58.1 -0.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.8

Max

58.7

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	26.292 51.415
Aktsiakasum	0.834
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+24.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-887M 3.2B
Eelmine avamishind	58.7
Eelmine sulgemishind	58.1

Uudiste sentiment

By Acuity

50%

157 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

51.1 / N/A Toetus ja vastupanu

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, XP

18. mai 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Claritev Shares Recover After Comments About DOJ

18. mai 2026, 23:55 UTC

Tulu

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

18. mai 2026, 20:25 UTC

Tulu

Correct: XP 1Q Total Client Assets BRL1.53T

18. mai 2026, 20:23 UTC

Tulu

XP 1Q Total Client Assets BRL1.53B

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Adj EPS BRL2.49 >XP

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Rev BRL4.73B >XP

18. mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. mai 2026, 19:00 UTC

Tulu

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. mai 2026, 18:17 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. mai 2026, 16:57 UTC

Omandamised, ülevõtmised, äriostud

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. mai 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Vinci Doesn't Set Out Financial Details of Deal

18. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. mai 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci Buys Canada's Modern Group of Companies

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

24.85% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 24.85%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

157 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.